Comparative Pharmacology
Head-to-head clinical analysis: VASCORAY versus VISIPAQUE 270.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VASCORAY versus VISIPAQUE 270.
VASCORAY vs VISIPAQUE 270
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
VASCORAY is a fixed combination of iodixanol and calcium sodium edetate. Iodixanol is a nonionic, dimeric, isotonic iodinated contrast medium that increases radiographic contrast by attenuating X-rays. Calcium sodium edetate chelates calcium, potentially reducing contrast-induced nephropathy risk.
Iodinated radiocontrast agent; attenuates X-rays, providing vascular and tissue opacification.
0.5-1.0 mL/kg intravenously as a single dose, not to exceed 5 mL/kg total.
Intraarterial or intravenous administration; dose depends on procedure, age, weight, cardiac output, and clinical condition. Typical adult dose: 50-150 mL of 270 mg I/mL (50-80 mL for coronary arteriography, 30-50 mL for left ventriculography; up to 250 mL total for multiple injections).
None Documented
None Documented
Terminal elimination half-life of 8-12 hours in patients with normal renal function; prolonged in renal impairment.
Terminal elimination half-life is approximately 1.5–2 hours in patients with normal renal function (creatinine clearance >60 mL/min). Prolonged in renal impairment, correlating with degree of kidney dysfunction.
Primarily renal (90% unchanged), with 10% biliary/fecal.
Renal excretion via glomerular filtration; >95% of administered dose eliminated unchanged in urine within 24 hours. Minimal biliary or fecal excretion (<1%).
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent